Harold Robert Meyer The ADD Resource Center · Reviewed Sept. 8, 2026 · Published Sept. 10, 2026
If you have seen the headline that adults with ADHD lose seven to nine years of life, you have seen a real finding from a peer-reviewed study, reported accurately. What the headline could not carry is what the number is: a population average, calculated across tens of thousands of people, in which a relatively small number of early deaths from accidents and suicide pull the whole average down. It is not a forecast for any one person, and it says nothing about what happens when ADHD is recognized and treated. This article lays out what the research shows, what it does not, and what remains unknown about why.
Key Takeaway
Diagnosed ADHD is associated with roughly double the mortality rate of the general population, and one UK study translated that into an apparent loss of about seven years for men and nine for women. The figures are consistent across countries, but they come almost entirely from diagnosed people, who tend to have more severe ADHD and more co-occurring conditions than the undiagnosed majority, so the population-wide gap is probably smaller. They are averages driven mostly by preventable early deaths, and no study has yet measured life expectancy in years for people who are treated.
Key Findings
- A UK matched cohort of 30,039 diagnosed adults found an apparent life-expectancy reduction of 6.78 years for men (95% CI 4.50–9.11) and 8.64 years for women (95% CI 6.55–10.91).
- A meta-analysis of eight studies covering 396,488 people with ADHD found a pooled mortality rate ratio of 2.13, with unnatural-cause deaths 2.81 times higher and the increase in natural-cause deaths not statistically significant.
- In a Swedish emulated trial of 148,578 newly diagnosed people, starting medication within three months of diagnosis was associated with 21 percent lower all-cause mortality and 25 percent lower unnatural-cause mortality over two years.
- Every one of these studies is observational and built on diagnosed samples. In population-based samples that include undiagnosed people, the mortality increase has been more modest. The studies establish that the gap exists and where the early deaths come from; they do not establish why, and nobody has measured the gap in treated people directly.
What was measured
The seven-and-nine-year figure comes from O’Nions and colleagues, 2025, who compared 30,039 UK adults with a recorded ADHD diagnosis against 300,390 people matched on age, sex, and primary-care practice, using the same life-table method a national statistics office uses. Apparent life expectancy was 73.3 years for men with diagnosed ADHD against 80.0 for comparison men, and 75.2 against 83.8 for women.
Three limits are worth holding onto. The database records date of death but not cause. The cohort was not split by treatment, so the study says nothing about medication. And the largest limit is who was counted.
Who was counted
Only about one in nine UK adults with ADHD is diagnosed. The people who reach a diagnosis are not a random sample of everyone with the condition: they are more likely to have severe symptoms, and more likely to carry the co-occurring conditions that are the rule rather than the exception in ADHD and that brought them to a specialist in the first place. In the UK cohort, every co-occurring condition examined, from depression and anxiety to epilepsy, heart disease, and harmful alcohol use, was more common in the diagnosed group at baseline. The authors say plainly that this may overstate the loss for the average person with ADHD.
Two comparisons point the same way. A British birth cohort followed from 1958, which rated childhood behavior in everyone rather than waiting for a diagnosis, found a more modest 1.6-fold increase in the probability of death by age 46 for children at the top of the scale. And in Quebec, where diagnosed ADHD prevalence in young people had reached 12.6 percent, the mortality difference against comparison young adults was smaller than in registers where diagnosis is rarer. Neither settles the question, but both are consistent with the same reading: the wider the net, the smaller the gap. The true population-wide figure is likely lower than seven and nine years; how much lower, nobody yet knows.
Why the gap is believed
Researchers have repeatedly found a doubling of mortality behind that figure. A Danish register study of 1.92 million people found an adjusted mortality rate ratio of 2.07, with accidents the leading cause. A Swedish cohort of 2.7 million found unintentional injury and suicide accounted for about two-thirds of deaths in the ADHD group, with psychiatric comorbidity, substance use disorder in particular, explaining much of the excess. A 2022 meta-analysis of eight ADHD mortality studies arrived at a rate ratio of 2.13. Different countries, different registers, one answer.
An earlier and often-quoted estimate from Barkley and Fischer, 2019 projected an 8.4-year loss for children with “hyperactive child syndrome”, rising to 11.1 years where ADHD persisted into adulthood. Those figures were modeled from self-reported health and lifestyle data at age 27 in 158 mostly male children and 81 controls, not from deaths. They are a forecast, not a count.
What changes with medication
No study that I have found has computed life expectancy in years for medicated versus unmedicated people. What exists is a comparison of death rates. In Li and colleagues, 2024, 148,578 newly diagnosed Swedes who filled a prescription within three months were compared against those who did not, over two years. Medication initiation was associated with a hazard ratio of 0.79 for all-cause mortality and 0.75 for unnatural-cause mortality; for natural causes, the ratio was 0.86, and the confidence interval crossed one. A Quebec cohort of 217,192 people under 25 found periods on medication carried a hazard ratio of 0.61 for all-cause mortality, confined to stimulants. A second Swedish emulated trial found medication associated with lower rates of suicidal behavior, substance misuse, transport accidents, and criminality: the very pathways the mortality studies identified.
Two years of follow-up is short, and people who fill a first prescription differ from those who do not in ways no register captures. A published commentary argued that stimulants carry their own cardiovascular and psychiatric risks; the UK authors replied by pointing to the Swedish mortality data. The medication finding is consistent and large, and it is still an association.
“I have watched people read a statistic like this as a sentence handed down. It is not. It is an average of lives lived with and without help, and the help is the part you control.” – Harold Robert Meyer
Why, exactly, is still not known.
The studies agree that the gap exists and that early deaths are concentrated in accidents, poisoning, and suicide. They do not settle why. Candidate explanations include comorbidity, impulsivity and risk-taking, co-occurring substance use and mood disorders, smoking and poor sleep, unemployment and financial strain, and delayed or absent treatment, and the UK authors argue that the diagnosed sample itself skews toward the sickest. These overlap; none has been isolated, and every study to date is correlational.
What is needed is stratification. Today’s figures that I am aware of lump together everyone with a diagnosis. Future studies need to report life expectancy separately by severity, by co-occurring condition and how many there are, by age at diagnosis, by sex, by treatment status and how long treatment lasted, and, most of all, in population samples that include the undiagnosed majority alongside the diagnosed minority. Add cause-of-death data to the life tables and follow-up longer than two years, and the question of how much of the gap belongs to ADHD itself, how much to what travels with it, and how much to selection can begin to be answered. Until that work is done, the figures appear to be correct for the people they describe, and the reasons remain a set of well-supported hypotheses.
We want to hear from you
Research can count deaths; it cannot easily ask why. You can. If you have ADHD, or you care for or treat someone who does, we would like to know what you think lies behind these numbers. Write to [email protected]. We read every message, and what we learn will shape future articles.
A note for clinicians and prescribers
The actionable content is the cause-of-death profile: injury, poisoning, and suicide early; late diagnosis carrying the highest ratio; and a gap the UK authors tie to smoking and untreated physical and mental health conditions. A stimulant prescription addresses the first cluster. Smoking, sleep, blood pressure, and weight belong in the annual review.
The next step
Don’t rewrite your will, and don’t stop buying green bananas, or canceling your subscriptions to your favorite publications. These are averages drawn from the most affected fraction of people with ADHD, and the biggest contributors to them, accidents, substance misuse, suicide, and smoking, are the things treatment and ordinary preventive care already target. If you are untreated, the evidence says that treatment is associated with fewer of exactly the deaths that drive the gap. If you are treated, the open question is the natural-cause column, which is a conversation about sleep, smoking, and blood pressure, not about fate. Take the cause-of-death list to your next appointment, ask which items are yours, and work on those.
Synopsis
A calm reading of the peer-reviewed evidence on ADHD and life expectancy. The 2025 UK life-table study found an apparent loss of 6.78 years for men and 8.64 for women among diagnosed adults, consistent with a doubled mortality rate replicated in Danish, Swedish, and pooled international data, with accidents and suicide the leading early causes. Swedish and Quebec cohorts show 21 to 39 percent lower all-cause mortality after starting medication, concentrated in unnatural causes; no study has measured life expectancy in years for treated people. The piece stresses that the figures come from diagnosed samples that over-represent severity and co-occurring conditions, so the population-wide gap is probably smaller; that the reasons remain unproven hypotheses needing stratified studies by severity, comorbidity, age at diagnosis, sex, and treatment; and invites readers to share their own views by email.
The author gratefully acknowledges Ronald H. Blumer for his valuable comments and suggestions on this article.
Topic: Research; Medication Audience: Adults with ADHD; Clinicians and prescribers; Parents and caregivers Keywords: life expectancy, mortality, unnatural causes, stratification, undiagnosed
Bibliography
Barkley, R. A., & Fischer, M. (2019). Hyperactive child syndrome and estimated life expectancy at young adult follow-up: The role of ADHD persistence and other potential predictors. Journal of Attention Disorders, 23(9), 907–923. https://doi.org/10.1177/1087054718816164
Catalá-López, F., Hutton, B., Page, M. J., Driver, J. A., Ridao, M., Alonso-Arroyo, A., et al. (2022). Mortality in persons with autism spectrum disorder or attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. JAMA Pediatrics, 176(4), e216401. https://doi.org/10.1001/jamapediatrics.2021.6401 ??? authors after the sixth not confirmed this session; expand to full APA list before publishing ???
Diallo, F. B., Pelletier, É., Vasiliadis, H.-M., Rochette, L., Vincent, A., Palardy, S., et al. (2022). Morbidities and mortality of diagnosed attention deficit hyperactivity disorder (ADHD) over the youth lifespan: A population-based retrospective cohort study. International Journal of Methods in Psychiatric Research, 31(1), e1903. https://doi.org/10.1002/mpr.1903
Dalsgaard, S., Østergaard, S. D., Leckman, J. F., Mortensen, P. B., & Pedersen, M. G. (2015). Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: A nationwide cohort study. The Lancet, 385(9983), 2190–2196. https://doi.org/10.1016/S0140-6736%2814%2961684-6
Jokela, M., Ferrie, J., & Kivimäki, M. (2009). Childhood problem behaviors and death by midlife: The British National Child Development Study. Journal of the American Academy of Child and Adolescent Psychiatry, 48(1), 19–24. https://doi.org/10.1097/CHI.0b013e31818b1c76
Li, L., Zhu, N., Zhang, L., Kuja-Halkola, R., D’Onofrio, B. M., Brikell, I., Lichtenstein, P., Cortese, S., Larsson, H., & Chang, Z. (2024). ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA, 331(10), 850–860. https://doi.org/10.1001/jama.2024.0851 · Free full text (PMC)
O’Nions, E., El Baou, C., John, A., Lewer, D., Mandy, W., McKechnie, D. G. J., Petersen, I., & Stott, J. (2025). Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: Matched cohort study. The British Journal of Psychiatry, 226(5), 261–268. https://doi.org/10.1192/bjp.2024.199 · Free full text (PMC)
Sun, S., Kuja-Halkola, R., Faraone, S. V., D’Onofrio, B. M., Dalsgaard, S., Chang, Z., & Larsson, H. (2019). Association of psychiatric comorbidity with the risk of premature death among children and adults with attention-deficit/hyperactivity disorder. JAMA Psychiatry, 76(11), 1141–1149. https://doi.org/10.1001/jamapsychiatry.2019.1944
Vasiliadis, H.-M., Lunghi, C., Rahme, E., Rochette, L., Gignac, M., Massamba, V., Diallo, F. B., Fansi, A., Cortese, S., & Lesage, A. (2024). ADHD medications use and risk of mortality and unintentional injuries: A population-based cohort study. Translational Psychiatry, 14, 128. https://doi.org/10.1038/s41398-024-02825-y · Free full text (PMC)
Zhang, L., Zhu, N., Sjölander, A., Nourredine, M., Li, L., Garcia-Argibay, M., Kuja-Halkola, R., Brikell, I., Lichtenstein, P., D’Onofrio, B. M., Larsson, H., Cortese, S., & Chang, Z. (2025). ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: Emulation of target trials. BMJ, 390, e083658. https://doi.org/10.1136/bmj-2024-083658 · Free full text (PMC)
Resources
From The ADD Resource Center
- Your ADHD needs one appointment a year that isn’t about the prescription
- How to talk to Your Doctor: Get the Care You Need
- Essential ADHD Doctor Appointment Checklist: Maximize Your Visit
- If ADHD Is a Neurobiological Condition, Why Are Coaching and Therapy Often Recommended?
External
- UCL news release on the life-expectancy study – includes the authors’ own caution about generalizing to undiagnosed adults
- Karolinska Institutet summary of the medication and mortality study
- University of Southampton summary of the BMJ emulated-trial study
About the Author
Harold Robert Meyer founded The ADD Resource Center in 1993 and has spent more than thirty years translating the lived experience of ADHD into practical guidance for individuals, families, and the clinicians and educators who work with them. He co-founded CHADD of New York in 1989 and went on to serve on CHADD National’s board and executive committee, including as Vice President of Finance. He was later elected to lead the Institute for the Advancement of ADHD Coaching. An author and international speaker, he has presented at the American Psychiatric Association Annual Meeting, CHADD national and local conferences, NYU Langone, Mount Sinai Medical Center, and Weill Cornell Medical College. Reach him at [email protected].
📚 Come back often — we add new evidence-based ADHD resources daily.
The ADD Resource Center [email protected] · +1 (646) 205-8080 · 127 West 83rd St., Unit 133, New York, NY 10024-0840 USA X · LinkedIn · Facebook · Substack · Newsletter
Please consider the environment before printing.
Our content is educational and informational only – not medical, legal, financial, or other professional advice, nor a substitute for it, and should not be relied on as such. We strive for accuracy, but errors or omissions occur and information becomes outdated. Some content and images may be created with AI assistance and, though reviewed before publication, may contain inaccuracies. Our screening tools are not diagnostic instruments. Verify independently and consult a qualified professional before acting on anything here.
In the USA and Canada, call or text 988 anytime for free mental health and suicide prevention support, or call 911 if someone is in immediate danger. The ADD Resource Center is independent from these services and is not liable for any actions taken by you or by these services.
Under GDPR and CCPA, you may request access to, correction of, or deletion of your personal data at [email protected].
© 2026 The ADD Resource Center. All rights reserved. For permission to reproduce, contact [email protected].